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Chronic myeloid leukemia (CML) is a clonal 
myeloproliferative disorder that results from 
the stable recurrent Philadelphia chromosomal 
translocation (Ph+) in hematopoietic stem cells 
(HSCs), giving rise to the oncogenic BCR-
ABL fusion protein (Nowell and Hungerford, 
1960; Bartram et al., 1983). The course of CML 
is biphasic, with a prolonged chronic phase (CP) 
that eventually progresses to a fatal blast-crisis 
phase (BP) that is characterized by accumulation 
of differentiation-arrested and therapy-resistant 
blast cells (Perrotti et al., 2010). Administration 
of BCR-ABL tyrosine kinase inhibitors (TKIs) 
can efficiently restrain CML-CP, but complete 
remission is difficult to achieve due to persistence 
of TKI-resistant leukemia-initiating cells (LICs) 
that may reestablish CML and cause disease re-
lapse (Druker et al., 2006; Crews and Jamieson, 
2013). These observations highlight the clini-
cal need to approach mechanisms of CML 
LIC’s persistence.
The presence of putative LICs in different 
types of leukemia and their clinical relevance 
has been determined experimentally (Bonnet and 
Dick, 1997; Eppert et al., 2011). LICs may orig-
inate from normal HSCs or from committed 
progenitors that share a core transcriptional 
“stemness” program with HSCs (Krivtsov et al., 
2006; Eppert et al., 2011). Wnt/-catenin sig-
naling is one of the important players in the 
stem cell pathways. Although the role of Wnt/ 
-catenin signaling in the regulation of self- 
renewal in normal HSCs remains under debate 
(Cobas et al., 2004; Jeannet et al., 2008; Koch et al., 
2008), its involvement in leukemogenesis and 
necessity for development of LICs is widely ac-
knowledged (Müller-Tidow et al., 2004; Malhotra 
and Kincade, 2009; Wang et al., 2010; Yeung et al., 
2010; Luis et al., 2012). In BCR-ABL–induced 
CML, Wnt/-catenin signaling is aberrantly acti-
vated and responsible for expanding the granu-
locyte/monocyte progenitor (GMP) pool in 
patients with blast crisis (Jamieson et al., 2004; 
Abrahamsson et al., 2009). Although deletion 
of -catenin in a BCR-ABL–induced CML 
mouse model led to impaired leukemogenesis 
(Zhao et al., 2007; Hu et al., 2009), delay of disease 
recurrence and abrogation of fully developed 
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Progression and disease relapse of chronic myeloid leukemia (CML) depends on leukemia-
initiating cells (LIC) that resist treatment. Using mouse genetics and a BCR-ABL model of 
CML, we observed cross talk between Wnt/-catenin signaling and the interferon-regulatory 
factor 8 (Irf8). In normal hematopoiesis, activation of -catenin results in up-regulation of 
Irf8, which in turn limits oncogenic -catenin functions. Self-renewal and myeloproliferation 
become dependent on -catenin in Irf8-deficient animals that develop a CML-like disease. 
Combined Irf8 deletion and constitutive -catenin activation result in progression of CML 
into fatal blast crisis, elevated leukemic potential of BCR-ABL–induced LICs, and Imatinib 
resistance. Interestingly, activated -catenin enhances a preexisting Irf8-deficient gene 
signature, identifying -catenin as an amplifier of progression-specific gene regulation in the 
shift of CML to blast crisis. Collectively, our data uncover Irf8 as a roadblock for -catenin–
driven leukemia and imply both factors as targets in combinatorial therapy.
© 2013 Scheller et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
Published October 7, 2013
http://jem.rupress.org/content/suppl/2013/10/02/jem.20130706.DC1.html 
Supplemental Material can be found at:
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
 o
n
 O
ctober 29, 2013
jem.rupress.org
D
ow
nloaded from
 
2240 -catenin and Irf8 in leukemia progression | Scheller et al.
shown in Fig. 1 A, -catenin activation led to up-regulation 
of proapoptotic and down-regulation of prosurvival genes that 
was also noted by others (Perry et al., 2011). Remarkably, 
genes associated with self-renewal and leukemogenesis, such as 
Meis1, Hoxa9, Runx2, Mef2c, and Mylk, were transcriptionally 
down-regulated. Using established myeloid (GM)- and eryth-
roid (E)-specific gene signatures (Månsson et al., 2007), we 
found that in Ctnnb1(Ex3)/+ LSK cells, E-specific gene ex-
pression was increased (e.g., Gata1, Ermap, Klf1, Pklr, and Epor), 
whereas myeloid gene expression (e.g., Elane, Csf1r, Csf3, Mpo, 
and Cebpa) was diminished, mirroring the prospective lineage 
commitment defect.
Expression of key transcription factors that orchestrate 
myeloid differentiation (Rosenbauer and Tenen, 2007) was 
validated by RT-PCR. Expression of Sfpi1 (Pu.1) and Cebpa 
mRNAs was strongly reduced and expression of Irf8 was up-
regulated (Fig. 1 B). Enhanced Irf8 expression was also evi-
dent by protein analysis (Fig. 1 C) and was consistent with the 
enrichment of Irf8 target genes (Tamura et al., 2005; Kubosaki 
et al., 2010) in the Ctnnb1(Ex3)/+ LSK gene expression sig-
nature (Fig. 1 D). Analysis of the Irf8 promoter region re-
vealed three consensus-binding sites for the -catenin target 
transcription factors Tcf/Lef1 (Tcf/Lef1-binding elements 
[TBEs], CTTTGAT and ATCAAAG, respectively) in a re-
gion 1.7 kb upstream of the transcriptional start site (Fig. 1 E). 
A -catenin/Lef1 construct enhanced Irf8 promoter (1710 
to +33)–driven reporter expression in a TBE2 site-dependent 
fashion (Fig. 1 F). Electrophoretic mobility shift assays 
(EMSAs) confirmed binding of -catenin/Lef1 to the TBE2 site 
(Fig. 1 G). These results identify Irf8 as a novel Wnt/-catenin 
target gene.
To explore the functional consequences of Irf8 up-regulation 
on myeloid lineage commitment of Ctnnb1(Ex3)/+ LSK cells, 
WT HSC- and progenitor-enriched Lin BM cells were 
transduced with a retroviral construct carrying Irf8 cDNA 
or 4-hydroxy-tamoxifen (4-OHT)–inducible Irf8 (Irf8-ERT2) 
and analyzed in CFU assays and by transplantation into lethally 
irradiated mice. Induction of Irf8 reduced the percentage of 
myeloid GFP+CD11b+ cells in animals (Fig. 1 H, top), while 
GFP+B220+ B cells remained constant (Fig. 1 H, bottom). 
Analysis of apoptosis showed increased Annexin V staining 
within the myeloid compartment (GFP+CD11b+), but not 
in B cells (GFP+B220+ cells; unpublished data). Furthermore, 
enforced expression of Irf8 reduced myeloid colony forma-
tion, in particular granulocyte-monocyte (GM)– and granu-
locyte (G)-CFUs (Fig. 1 I). In accordance with previous 
findings, expression of a stabilized form of -catenin also re-
duced colony formation (Fig. 1 I). In a reciprocal experiment, 
a stabilized -catenin construct was introduced into Irf8/ 
progenitors. In contrast to the WT cells, introduction of stabi-
lized -catenin into Irf8-deficient Lin BMCs barely affected 
proliferation and colony formation (Fig. 1 J). Altogether, con-
stitutive activation of Wnt/-catenin signaling in HSCs re-
sulted in repression of self-renewal–associated genes, increased 
apoptosis, and altered lineage priming that may provide the 
explanation for early lethality of mice after -catenin activation. 
CML LICs were only achieved with Imatinib cotreatment 
(Heidel et al., 2012). These studies suggested that canonical Wnt 
signaling could become a druggable target in patients with 
minimal residual CML disease (Heidel et al., 2012).
Another recurrent lesion in CML pathogenesis involves 
the IFN-regulatory factor 8 (Irf8), which has been established as 
a tumor suppressor in CML (Holtschke et al., 1996; Hao and 
Ren, 2000; Deng and Daley, 2001; Tamura et al., 2003; 
Burchert et al., 2004). Patients with CML show reduced Irf8 
expression, and successful CML therapy is associated with a 
restoration of Irf8 level (Schmidt et al., 1998). Targeted dele-
tion of Irf8 in the mouse leads to development of a CML-like 
disease (Holtschke et al., 1996; Scheller et al., 1999). Down-
regulation of Irf8 is required for murine BCR-ABL–inducible 
CML disease, whereas coexpression of Irf8 repressed the mito-
genic activity of BCR-ABL in vivo (Hao and Ren, 2000) and 
in vitro (Tamura et al., 2003; Burchert et al., 2004). Loss of 
Irf8 synergized with different oncogenes and induced myelo-
blastic transformation (Schwieger et al., 2002; Gurevich et al., 
2006; Hara et al., 2008); however, progression of Irf8/ CML-
like disease in mice occurred rarely and only after long latency 
(Holtschke et al., 1996). These results suggested that Irf8 defi-
ciency is a prerequisite but not sufficient for malignant trans-
formation and requires an additional genetic lesion for blast 
crisis progression.
Irf8 functions as an anti-oncoprotein that inhibits expres-
sion of myc, an important target gene of BCR-ABL (Tamura 
et al., 2003), negatively controls anti-apoptotic genes, such as 
bcl2, bcl2l1 (bcl-xl), or Ptpn13 (Fas-associated phosphatase-1), 
and enhances the expression of proapoptotic genes, such as 
caspase-3 (Gabriele et al., 1999; Burchert et al., 2004). Recent 
studies have also suggested a link between Irf8 deficiency and 
increased expression and activity of -catenin that may asso-
ciate with poor prognosis and CML-BP transition (Huang 
et al., 2010).
In this study, we demonstrate that cross talk between ca-
nonical Wnt and IFN signaling determines development of 
CML-LICs and represents a BCR-ABL–independent mech-
anism of disease progression underlying the acquisition of re-
sistance to Imatinib at later stages of CML. Because elimination 
of -catenin did not affect normal HSCs and because Irf8  
antagonized BCR-ABL–induced leukemia, targeting of both 
pathways together with TKI treatment may pave the way to 
more effective combinatorial therapeutic strategies in the 
treatment of advanced CML.
RESULTS
Irf8 is a functional downstream target of -catenin
Activation of Wnt/-catenin signaling in the hematopoietic 
system of mice has previously been shown to result in im-
paired lineage differentiation and rapid death of the animals 
(Kirstetter et al., 2006; Scheller et al., 2006). Gene expression 
profiling was now used to explore consequences of -catenin 
activation in the HSC enriched lineage-negative (Lin) Sca-1+ 
c-Kit+ (LSK) bone marrow compartment, using MxCre+ 
Ctnnb1(Ex3)fl/+ and control MxCreCtnnb1(Ex3)fl/+ mice. As 
JEM Vol. 210, No. 11 
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Figure 1. Irf8 is a downstream effector of activated -catenin and restrains myeloid development. (A) Alteration of gene expression after  
-catenin activation in HSC. Overview of selected differential gene expression patterns in sorted LSKs from MxCre+Ctnnb1(Ex3)fl/+ (denoted Ctnnb1(Ex3)/+; 
, deleted) compared with control MxCreCtnnb1(Ex3)fl/+ (denoted Ctnnb1(Ex3)fl/+; fl, floxed). Genes were considered differentially expressed at a fold change 
(log2): ≥1.5 or ≤1.5; P < 0.05. (B) Representative quantitative real-time RT-PCR (qRT-PCR) for the indicated targets in sorted LSKs. Values are standard-
ized to expression of -actin and are presented as fold induction, relative to expression in control LSK cells (set as 1). Value for Cebpa from Ctnnb1(Ex3)/+ 
LSK is 0.016 ± 0.015. Data are representative of three experiments. Error bars indicate SD, n = 3. (C) Immunoblot analysis of Irf8 protein in lineage de-
pleted (Lin) BM cells. Total protein extracts of poly(I:C)-treated controls and Ctnnb1(Ex3)/+ mice (n = 3) were analyzed using an antibody against mouse 
Irf8. Tubulin staining was used as loading control. (D) GSEA comparison of the Ctnnb1(Ex3)/+ against control LSKs for enrichment of Irf8-regulated genes. 
NES and p-values are indicated. (E) Identification of the Tcf/Lef1 binding sequences in the Irf8 promoter (Shtutman et al., 1999). A schematic representa-
tion of the Irf8 promoter structure with sequences of three putative TBEs. (F) Luciferase reporter assay showing the effect of -catenin on the Irf8 pro-
moter activity. Four Irf8 promoter fragments, F1/F0 (1710 to +33), F2/F0 (1582 to +33), F3/F0 (1318 to +33), and F2*/F0 with mutation in TBE2 
(1582 to +33, mutation indicated by asterisks), were PCR amplified from mouse genomic DNA and cloned into the pGL3 basic Luciferase vector.  
293T cells were cotransfected with respective reporter constructs, with or without chimeric -catenin/Lef1 expression plasmid and were analyzed after 48h.  
-Galactosidase construct was cotransfected to each sample to normalize transfection efficiency. The ratio of reporter luciferase activity to control  
-galactosidase activity is indicated. Data are representative of three experiments. Error bars indicate SD, n = 3. (G) EMSA showing that Lef1 binds to Irf8 
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depicted). Altogether, the changes in BM and in extramedul-
lary organs were characterized by depletion of the immature 
stem and GMP-progenitor compartments and a profound re-
duction of the CML-like phenotype in Irf8-deficient cells 
upon -catenin deletion.
Because -catenin may regulate self-renewal (Reya et al., 
2003), we examined whether loss of -catenin alters the clo-
nogenic potential and self-renewal capacity of Irf8/ cells. 
When BM and/or spleen cells were plated in semisolid me-
dium, the number of colonies was strongly reduced in the 
DKO (Fig. 2 H, and not depicted for spleen). Serial replating 
showed that WT and Irf8/ cells could be passaged more 
than four times, whereas DKO cells failed to replate beyond 
the second passage (Fig. 2 I). Decreased serial replating poten-
tial and colony formation suggested that deletion of -catenin 
restricted self-renewal of Irf8-deficient cells. Thus, unlike in 
Irf8-proficient cells, where -catenin was dispensable for colony 
formation (Cobas et al., 2004; Jeannet et al., 2008; Koch et al., 
2008), self-renewal and proliferation of preleukemic Irf8/ 
cells depend on -catenin.
Enhanced -catenin activity drives Irf8/ CML into blast crisis
A chronic CML-like phase develops in Irf8/ mice very rap-
idly with 100% penetrance, but transition to blast crisis occurs 
rarely and only after long latency (not depicted; Holtschke 
et al., 1996). This points to additional genetic lesions, which 
are required for transition into the acute BP. Considering the 
observation that the amplitude of Wnt/-catenin signaling 
may control preleukemic and leukemic stem cells (Lane et al., 
2011), we examined whether activation of -catenin could 
promote Irf8-deficient leukemia. Irf8/ mice were crossed 
to MxCre+Ctnnb1(Ex3)fl/+ or to control MxCreCtnnb1(Ex3)fl/+ 
mice and their BM was transplanted into lethally irradiated 
congenic WT recipients (B6.SJL, Ly5.1). After successful re-
constitution (85–99% of donor cells), recipients were treated 
with poly(I:C) to activate Wnt/-catenin signaling.
Recipients containing Irf8/Ctnnb1(Ex3)/+ mutant cells 
showed extended survival, as compared with recipients 
In addition, our experiments revealed Irf8 as a novel Wnt/ 
-catenin–activated target gene that, in response to Wnt/-catenin 
signaling, limits myeloid differentiation and proliferation.
Wnt/-catenin signaling is essential for Irf8-deficient CML
Irf8 deficiency endows myeloid progenitors with proliferative 
and survival advantages (Gabriele et al., 1999; Scheller et al., 
1999). Furthermore, a recent study showed that Irf8 might 
modulate the stability of -catenin (Huang et al., 2010), rais-
ing the possibility that both pathways are mechanistically 
connected. To examine the functional significance of -catenin 
in the development of Irf8/ CML-like disease, we condi-
tionally deleted -catenin in Irf8/ BM cells by combining 
Irf8-null alleles with MxCre-inducible -catenin floxed alleles 
(Huelsken et al., 2001; Jeannet et al., 2008). BM cells from 
inducible Irf8/MxCre+Ctnnb1fl/fl (denoted as DKO) and 
noninducible Irf8/MxCreCtnnb1fl/fl (denoted as Irf8/) 
mice were used for reconstitution of lethally irradiated con-
genic WT recipients (B6.SJL, Ly5.1) and -catenin deletion 
upon administration of poly(I:C) was induced after stable en-
graftment and monitored by PCR (Fig. 2, A–C). Although 
deletion of -catenin did not affect hematopoiesis in the WT 
background (Jeannet et al., 2008), myeloproliferation was 
strongly affected in the Irf8-deficient background. Analysis of 
recipients bearing DKO cells revealed reduction of peripheral 
white blood cell (WBC) and of spleen weight within 30 d 
after -catenin deletion (Fig. 2, D and E). The number of 
DKO LSK cells in BM and in spleen was profoundly reduced 
due to impaired frequencies of LT-HSCs (LSK, Flt3CD150+) 
and ST-HSCs (LSK, Flt3CD150) compared with the re-
cipients with single Irf8/ (Fig. 2 F). The absolute number 
and frequency of DKO GMPs was strongly reduced as well 
(P < 0.0001), whereas both common myeloid progenitors 
(CMPs) and megakaryocyte/erythrocyte progenitors (MEPs) 
remained unchanged (Fig. 2 G). Loss of -catenin did not 
alter the differentiation potential or apoptosis of DKO LSK 
and myeloid progenitors (LinSca-1c-kit+); however, the 
number of mature granulocytes was reduced, whereas eryth-
roid and lymphoid cell numbers were similar to WT (not 
Tcf/Lef1 sites. 293T cells were transfected with pCG-Lef1-HA or with a mock control. Nuclear extracts were incubated with an 32-P–labeled probe con-
taining an Irf8 Tcf/Lef1 site alone or with the addition of unlabeled competitors: the same WT Irf8 Tcf construct, or a mutated Irf8 Tcf construct (CTTTGAT 
to CTTTGGC), or a control oligonucleotide for a known human Cyclin D1 Tcf site without and with mutation (CTTTGAT to CTTTGGC). For supershift experi-
ments, 2 µl anti-HA antibody (Santa Cruz Biotechnology, Inc.) was added. Incubation of nuclear extracts with an 32-P–labeled probe containing a mu-
tated Irf8 Tcf site (CTTTGAT to CTTTGGC) did not show specific binding or supershift. Positions of the Lef1 protein (Lef1), the supershift band (ss), and free 
probe are indicated. (H) Overexpression of Irf8 blocks myeloid differentiation in vivo. Lin WT BM cells were transduced with a 4-OHT–inducible Irf8-ERT2 
or an empty control (ERT2) vectors. Cells were transplanted in lethally irradiated WT mice (n = 5 for each transduction). Relative changes of GFP-positive 
myeloid (CD11b+) and B-lymphoid (B220+) in peripheral blood plotted as percentages against time (weeks) after 4-OHT–mediated induction. Data are 
representative of two experiments. Error bars indicate SD, n = 5. (I) CFU assay in methylcellulose (M3434) from GFP+-sorted BM cells retroviral infected 
with control (MSCV-IRES-eGFP), Irf8, and the stabilized form of -catenin (-cat*; -catenin MSCV--catGSK-IRES-eGFP). Numbers of colonies per 104 
cells plated are shown. Colonies were classified into granulocyte-macrophage (CFU-GM), macrophage (CFU-M), and granulocyte (CFU-G). Data represent 
the mean ± SD from three independent samples. (J) Irf8 deficiency rescues myelopoiesis after activation of -catenin in vitro. Lin BM cells from WT and 
Irf8/ mice were transduced with stabilized form of -catenin (-cat*) or control empty retrovirus; GFP+ cells were sorted and assessed for myeloid 
differentiation in CFU assay. Colonies were counted and colony type confirmed by morphological analysis (May-Grunwald-Giemsa staining). Mean values 
± SD from one representative experiment performed in triplicate out of three independent experiments is displayed. Statistics: (B, F, and H) Student´s t 
test. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
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neutrophilia was replaced by immature myeloid blasts (Fig. 3 E, 
bottom), and mice became anemic, moribund, or died. The 
number of differentiated WBCs in peripheral blood and BM 
cellularity was reduced (Fig. 3, B–D, red bars) and accompa-
nied by development of a severe diffuse BM fibrosis, which 
in human is known to correlate with an unfavorable course 
of CML disease (Buesche et al., 2007). The number of red 
cells and platelets dropped (Fig. 3, F and G), and the spleen 
was enlarged, showing hyperplasia of red pulp and increased 
myelo-erythropoiesis with undifferentiated features (Fig. 3, 
H and I). Histological inspection revealed massive hemato-
poietic infiltrates in liver and pulmonary tissue (Fig. 3 I).
receiving single mutant Ctnnb1(Ex3)/+ cells (Fig. 3 A), probably 
due to the apoptosis resistance of Irf8-deficient cells (Gabriele 
et al., 1999; Scheller et al., 1999). Deletion of a single Irf8  
allele (Irf8+/ Ctnnb1(Ex3)/+) failed to increase survival, suggest-
ing that complete loss of Irf8 was required to overcome the 
lethality after -catenin stabilization (unpublished data). 10 d 
post injection (dpi) with poly(I:C), recipients bearing Irf8/ 
Ctnnb1(Ex3)/+ cells displayed increased numbers of WBC and 
BM cells, with predominance of mature granulocytes (Fig. 3, 
B–D [pink bars, 10 dpi] and E [middle]) representing initial 
chronic CML-like disease, similar to Irf8/ mice. However, 
at 20 dpi after -catenin activation, the initially prevalent 
Figure 2. Irf8-deficient CML requires  
-catenin. (A) Schematic representation of 
the experimental procedures and genotypes 
used for BM cell transplantation into lethally 
irradiated recipients. WT, noninducible Irf8/ 
MxCre–Ctnnb1fl/fl (Irf8/) and inducible dou-
ble knockout mutant Irf8/MxCre+Ctnnb1fl/fl 
(DKO) BM cells (Ly5.2+) were injected into 
lethally irradiated congenic B6.SJL (Ly5.1+) 
hosts, n = 10 recipients for each genotype. 
After 6 wk, reconstituted recipients were 
treated with poly(I:C) three times every 2nd d. 
(B) BM and spleen engraftment of donor-
derived cells (Ly5.2+) in B6.SJL (Ly5.1+) recipi-
ents 30 d after poly(I:C) treatment. (C) Whole 
BM and spleen from B6.SJL recipients geno-
typed for deletion of -catenin. (D and E)  
-Catenin deletion reduces Irf8/ myelopro-
liferative disease. Three to four mice per geno-
type were used to determine number of WBC 
in peripheral blood (D) and the mean weights 
of spleen from recipient mice ± SD trans-
planted with WT, Irf8/, or DKO cells 30 dpi 
with poly(I:C) (E). (F and G) -Catenin deletion 
results in reduction of stem and progenitor 
cells in recipients bearing DKO cells. Data rep-
resent mean ± SD from one experiment 30 d 
after the last p(I:C) injection, three to four 
mice per genotype were used. (F) Displayed 
are absolute number of LSKs in BM (left) and 
frequency of LSK in spleen (right). LSK com-
partment was subfractioned into LT-HSC and 
ST-HSC based on the surface expression of 
CD150 and Flt3 by FACS. (G) Absolute number 
of myeloid progenitors, separated as CMP, 
GMP, and MEP in BM (left) and their frequency 
in spleen (right) by FACS is shown. (H) Number 
of colonies derived from BM cells of recipients 
(described in D and E) tested in CFU assay. 
CFU per 2 × 104 cells were counted 7 d after 
cultivation and absolute numbers per femur 
and tibia are shown. Error bars indicate SD of 
mean number of colonies from triplicate cul-
tures of each mouse (n = 3 in each group).  
(I) Serial replating assay of 1 × 104 BM cells in methylcellulose medium from indicated genotypes. Colonies were counted after 5 d. The same number of 
cells was used for replating (five rounds). Error bars indicate SD of mean number of colonies from triplicate cultures of each mouse (n = 3 in each group). 
Results are representative of two determinations performed with BM and spleen cells. Statistics: (D–I) Student´s t test. *, P < 0.05; ***, P < 0.0001.
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block of granulocytic differentiation (Fig. 4, C and D). Col-
lectively, these results showed that conditional activation of 
-catenin shifts the initial CP of the Irf8/ CML-like disease 
into a fatal BP.
Next, we analyzed the cellular distribution of -catenin 
during disease progression. Elevated amounts of -catenin 
protein were found in the nuclear fraction of single Irf8/ Lin 
BM cells, which correlated with activated Wnt/-catenin 
signaling and was even more increased in double mutated 
Irf8/Ctnnb1(Ex3)/+ cell nuclei (Fig. 4 E). This indicates that 
the level of -catenin activation could be responsible for dis-
ease progression and that enhanced -catenin activation in 
Irf8/Ctnnb1(Ex3)/+ cells is a prerequisite for shifting the initial 
CP of the Irf8/ CML-like disease into a fatal blast crisis with 
accumulation of GMP-like blasts.
To further examine how activated -catenin drives dis-
ease progression, we performed immunophenotyping in sin-
gle Irf8/ cells and Irf8/Ctnnb1(Ex3)/+ cells. The frequency 
and absolute number of phenotypic HSCs (LSKs compart-
ment) was reduced in the BP compared with the CP-like 
phase of disease (Fig. 4, A and B, top). Analysis of the myeloid 
progenitor compartment indicated a severe reduction in the 
number of CMPs and MEPs during disease progression 
(Fig. 4 A, bottom), whereas the number of GMPs remains 
increased, in comparison with control mice (Fig. 4, A and B, 
bottom). Granulocytic maturation stages were further exam-
ined to assess the differentiation block of leukemic cells. Dur-
ing the BP, recipients bearing Irf8/Ctnnb1(Ex3)/+ cells 
displayed more promyelocytes (2.1 vs. 0.8%) and a strong 
reduction of mature granulocytes (0.06 vs. 16%), reflecting a 
Figure 3. Activation of -catenin accel-
erates CML-like disease of Irf8/ mice 
into blast crisis. (A) Kaplan-Meier survival 
curves of B6.SJL recipients transplanted with 
control MxCreCtnnb1(Ex3)fl/+ (denoted as 
Ctnnb1(Ex3)fl/+, n = 18), MxCre+Ctnnb1(Ex3)fl/+ 
(denoted as Ctnnb1(Ex3)/+, n = 20), Irf8/ 
MxCreCtnnb1(Ex3)fl/+ (denoted as Irf8/ 
Ctnnb1(Ex3)fl/+, n = 16), and Irf8/MxCre+ 
Ctnnb1(Ex3)fl/+ (denoted as Irf8/Ctnnb1(Ex3)/+, 
n = 20) are shown, and poly(I:C) injections are 
indicated as arrowheads. Log-rank (Mantel-
Cox) test. ***, P < 0.0001. (B–H) Comparison of 
hematopoietic parameters during progression 
of CML-like disease from initial phase (10 dpi 
with poly(I:C), pink) to BP (30 dpi, red) versus 
Irf8+/+MxCreCtnnb1(Ex3)fl/+ (Ctrl). (B) Absolute 
number of WBCs in peripheral blood (×106/ml).  
(C) BM cells (BMC, ×106 cells/femur+tibia).  
(D) Percentage of granulocytes in peripheral 
blood. (E) A representative May-Grunwald-
Giemsa staining of BM smears from recipients 
bearing control and double mutated Irf8/ 
Ctnnb1(Ex3)/+ cells after 10 dpi and in BP  
(30 dpi) are shown. Bars, 20 µm. (F) RBC (106/µl) 
counts. (G) Platelet counts (PLT, 106/µl).  
(H) Weights of the spleens (in milligrams) are 
shown. Results are displayed as mean values ± 
SEM from six to eight mice in each group. 
Statistics: (B–H) Student´s t test. n.s., not sig-
nificant; *, P < 0.05; ***, P < 0.0001. (I) Repre-
sentative histology (H&E stain) of CML-like BP 
disease in spleen, liver, and lung from recipi-
ents bearing Irf8/Ctnnb1(Ex3)/+ versus con-
trol (Ctrl) cells. Bars: (spleen) 200 µm; (lung) 
100 µm; (liver) 50 µm.
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(Fig. 5 C, mean P = 0.8666). These results corroborated the 
presumption of simultaneous deregulation of IRF8 and Wnt/ 
-catenin in human CML progression.
Activation of -catenin determines the extent of gene 
regulation in leukemic GMPs from chronic to BP transition
Similar to the results shown here, expansion of progenitors 
and reduction of HSC was found in the BM from patients 
with blast-crisis CML (Jamieson et al., 2004). We therefore 
analyzed gene expression from sorted murine LSK and GMP 
populations after development of clinically evident blast crisis 
Decreased expression of Irf8 and increased activation of 
-catenin are clinically relevant (Schmidt et al., 2001; Jamieson 
et al., 2004). We referred to published datasets to assess fre-
quency of compound lesions (Radich et al., 2006). We ob-
served a striking down-regulation of IRF8 expression during 
CML progression in a large cohort of accelerated and BP of 
CML samples, as compared with the CP (P < 0.05; Fig. 5 A). 
A significant proportion of these patients also showed accom-
panying up-regulation of Wnt/-catenin target genes (Fig. 5 B, 
mean P < 0.05), whereas BP patients with normal- or up-
regulated levels of IRF8 showed no significant mean p-value 
Figure 4. Immunophenotyping of HSCs 
and myeloid progenitors from leukemic 
mice. (A) Reorganization of the immature BM 
compartments in transplanted mice in differ-
ent stages of disease progression. Representa-
tive FACS profiles for LSKs (top), represented 
as percentage of lineage-negative LSK BM 
fraction and myeloid progenitors (bottom), 
separated by FcR versus CD34 staining as 
GMPs, CMPs, and MEPs from recipients trans-
planted with control Ctnnb1(Ex3)fl/+, Irf8/ 
(CP), and Irf8/ Ctnnb1(Ex3)/+. (B) Absolute 
numbers of LSKs (top) and GMPs (bottom) in 
BM per femur and tibia. (C) Expansion of pro-
myelocytes expressing activated -catenin in 
the BP phase. Lin, Sca-1–negative BM cells 
in control, CP, or BP were gated into c-Kit+ 
CD34+ and c-KitCD34 fractions (left). Pro-
myelocytes were gated based on c-Kit+ 
CD34+Gr-1+ immunophenotype (middle) and 
mature granulocytes were gated based on c-Kit 
CD34Gr-1+ immunophenotype (right). Fre-
quencies are represented as percentage 
among all live cells. (D) Absolute numbers of 
promyelocytes (top) and granulocytes (bottom) 
in BM per femur and tibia. Data in B and D  
are mean ± SD for 8–10 mice of each geno-
type. Statistics: (B and D) Student´s t test.  
*, P < 0.05; ***, P < 0.0001. (E) Immunoblot 
analysis of -catenin protein localization in 
stem and progenitor cells enriched Lin BM 
fractions. The cytoplasmic (cy) and nuclear 
(nu) fractions were analyzed using an anti– 
-catenin antibody for the poly(I:C)-treated 
control Ctnnb1(Ex3)fl/+, Irf8/Ctnnb1(Ex3)fl/+  
(n = 3), and double-mutated Irf8/Ctnnb1(Ex3)/+ 
(n = 4) cells. -Actin staining served as  
loading control.
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expression profile that is different from the control but is 
similar to the Irf8/ GMPs (unpublished data). Hierarchical 
clustering using the Ward algorithm and Pearson’s correla-
tion identified a large group of genes with similar expression 
in both GMPs from CP and BP, but significantly enhanced 
deregulation in the Irf8/Ctnnb1(Ex3)/+ GMP from BP, estab-
lishing a progression-specific signature (PSS; Fig. 6 F; available 
online under accession no. GSE49054). All transcripts dereg-
ulated in PSS from Irf8/Ctnnb1(Ex3)/+ GMPs showed a 
significantly restricted expression level in the CP compared 
with the acute BP (Fig. 6 G). These results suggest that the bio-
logical differences between chronic and BPs of myeloid leu-
kemia are likely mediated by quantitative alterations in gene 
expression and that activated -catenin controls the extent of 
gene regulation.
Classification of PSS genes according to their functional 
annotation (GO/KEGG) revealed up-regulation of genes that 
belong to metabolic pathways, including lipid metabolism 
and glycolysis (Fig. 6 H). Moreover, progression was associ-
ated with up-regulation of MAPK, insulin, and VEGF signal-
ing pathway genes, in addition to cytoskeletal and adhesion 
molecule alterations. Remarkably, ABC transporter genes, 
including Abcb10, Abcc2, and Abcc5, which are implicated in 
the development of drug resistance in human CML, were highly 
up-regulated, suggesting involvement of Wnt/-catenin sig-
naling in the regulation of ABC-transporter gene transcrip-
tion. Compared with the CP, the -arrestin2 (Arrb2) and Bcl6 
genes were up-regulated (accession no. GSE49054), both of 
which have recently been suggested as critical for LIC survival 
and progression of BCR-ABL–transformed CML in humans 
and in a mouse model (Hurtz et al., 2011; Fereshteh et al., 2012). 
in recipients bearing Irf8/Ctnnb1(Ex3)/+ cells and compared 
them with controls (Ctnnb1(Ex3)fl/+). The numbers of differ-
entially expressed genes in leukemic Irf8/Ctnnb1(Ex3)/+ 
GMPs were higher than in LSKs (Fig. 6 A), indicating that 
major differences occur at the level of GMP rather than 
at the LSK stage. Compared with LSKs, gene profiling of 
Irf8/Ctnnb1(Ex3)/+ GMPs showed strong enrichment of a 
leukemic self-renewal–associated signature, as reported for an 
AML-AF9–transformed functionally defined L-GMP popu-
lation (Krivtsov et al., 2006; Fig. 6 B) and for up-regulated 
genes derived from human CML patients (Diaz-Blanco et al., 
2007; Fig. 6 C). Furthermore, reduction of LSK and accumu-
lation of GMP in the BP was consistent with an increased 
proapoptosis-associated gene set seen in Irf8/Ctnnb1(Ex3)/+ 
LSK in contrast to the Irf8/Ctnnb1(Ex3)/+ GMPs gene pro-
files (Fig. 6 D).
Interestingly, applying established myeloid (GM)- and 
megakaryocyte/erythroid (MkE)-specific gene sets (Månsson 
et al., 2007), the GMP profiles of Irf8/Ctnnb1(Ex3)/+ cells 
showed enrichment for GM signatures and depletion for MkE 
signatures (Fig. 6 E), whereas single mutated Ctnnb1(Ex3)/+ 
GMP profiles displayed inverse gene set enrichment (Fig. 1 A), 
reflecting defects in lineage commitment. These results sug-
gest that Irf8 is involved in the suppression of myeloid-specific 
genes by activated -catenin.
To examine how enhanced -catenin signaling advances 
Irf8/ CML-like disease into BP, we compared global gene 
expression in GMP samples from three phenotypes: control, 
single Irf8/ (denoted as CP), and double mutated Irf8/ 
Ctnnb1(Ex3)/+ (denoted as BP). Unsupervised analysis dem-
onstrated that Irf8/Ctnnb1(Ex3)/+ GMPs from BP have an 
Figure 5. Gene expression profile in BM 
or PB from chronic and BP CML patients. 
(A) Expression of IRF8 (P < 0.05) in BM or PB 
from CP (blue), accelerated phase (pink), and BP 
(red) CML patients is displayed in linear scale. 
Data were analyzed using R/Bioconductor, and 
moderated t-statistics using the limma pack-
age. (B and C) The samples were separated into 
IRF8-down (IRF8-DN, B) and IRF8-up-regulated 
(IRF8-UP, C) subgroups. Heatmaps show repre-
sentative Wnt target genes. Microarray data 
were taken from the Gene Expression Omnibus 
under accession no. GSE4170.
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Enhanced leukemic potential of BCR-ABL–induced LICs  
and Imatinib resistance depends on cooperation between  
-catenin activation and Irf8 deficiency
The murine BCR-ABL–mediated CML model was used to 
validate the finding of combined -catenin and Irf8 lesions 
in human CML. Lin BMC from control (WT) and double 
mutant Irf8/MxCre+Ctnnb1(Ex3)fl/+ mice were transduced 
with a retrovirus expressing the p210BCR-ABL-GFP gene 
(Li et al., 1999). Transformation efficiency was indistinguish-
able, but Irf8/MxCre+Ctnnb1(Ex3)fl/+ cells without -catenin 
Among the down-regulated genes, proapoptotic genes and 
genes involved in ubiquitin-mediated proteolysis (Cul4b, 
Nedd4, Fbxw4, Ubfd1, and Rhobtb1) were prominent and di-
minished ubiquitin-mediated proteolysis has previously been 
associated with -catenin stabilization (Aberle et al., 1997). 
Collectively, our data suggest that stepwise enhancement of 
-catenin drives Irf8-deficient CML into acute BP. These 
blasts display more primitive but deregulated stem cell fea-
tures with enrichment of genes associated with leukemic self-
renewal and drug resistance.
Figure 6. Gene expression profile of leukemic LSKs and GMPs. (A) Comparison of significantly differently expressed genes between control 
Ctnnb1(Ex3)fl/+ and Irf8/Ctnnb1(Ex3)/+ cells from sorted LSK (top) and GMP (bottom) populations is shown in Volcano plots. The negative log10-transformed 
p-values are plotted against log2 fold change. Red dots represent significant differentially expressed probe sets. (B–E) Comparison by GSEA between  
LSKs (top) and GMPs (bottom) from Irf8/Ctnnb1(Ex3)/+. Each population was compared individually to LSK and GMPs from control Ctnnb1(Ex3)fl/+ profiles. 
Plots show enrichment/depletion of leukemic self-renewal associated genes derived from MLL-AF9-transduced L-GMPs (B) and up-regulated gene set 
from human CML patients (165 genes in enrichments core; C) and genes involved in proapoptotic signature (D; Reactome). (E) GSEA plots from Irf8–/–
Ctnnb1(Ex3)∆/+ GMPs compared with control Ctnnb1(Ex3)fl/+ GMPs showing enrichment/depletion of granulocytic/monocytic- (GM-Sig, top) and mega-
karyocytic/erythroid (MkE-Sig, bottom)-associated gene expression set. The NES and p-values are indicated on each plot. (F) Heatmap of significantly 
deregulated genes in GMPs from BP and CP compared with control establish a PSS; Pearson’s correlation coefficient and Ward’s method were used.  
(G) Expression values of up- and down-regulated genes as depicted in PSS. BP (red, genes in Irf8–/–Ctnnb1(Ex3)∆/+ GMPs) as compared with CP (blue, genes 
in Irf8–/– GMPs) and control (green, genes in Ctnnb1(Ex3)fl/+ GMPs). The y-axis represents different genes from the PSS; the x-axis depicts the median expression 
value for every gene, which were row-wise median centered. (H) Gene ontology classification of genes selectively expressed in PSS. The percentage of 
each functional category represents numbers of gene transcripts that were more abundant in PSS profile than in control GMPs (plus value, up-regulated; 
minus value, down-regulated genes).
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transplantation [BMT]). The control recipient group, con-
taining WT-BCR-ABL–transformed LICs (WT-LICs), suc-
cumbed to BCR-ABL–induced CML development with 
increased granulopoiesis and splenomegaly within 4 wk after 
transplantation (Fig. 7 C). In contrast, recipients bearing 
BCR-ABL–expressing Irf8/Ctnnb1(Ex3)/+ cells (Irf8/ 
Ctnnb1(Ex3)/+-LIC) developed an aggressive acute BP shortly 
after -catenin activation (Fig. 7 C). Importantly, the disease 
latency of Irf8/Ctnnb1(Ex3)/+ transplanted mice was signifi-
cantly (P = 0.0004) shorter in the presence of BCR-ABL 
activation showed higher myeloid differentiation rate and ac-
cumulation of CD11b+c-Kit+ population in vitro (Fig. 7 A). 
After expansion in vitro, GFP+ cells from control cultures 
contained c-Kit+CD11b+ and c-Kit+CD11b populations, 
whereas Irf8/MxCre+Ctnnb1(Ex3)fl/+ cultures consisted mainly 
of a c-Kit+CD11b+ population (Fig. 7 B). To determine the 
leukemia-initiating potential of BCR-ABL–transformed cells 
(LICs) in vivo, GFP+c-Kit+CD11b+ cells (that also contained 
a GMP fraction) were sorted and transplanted into syngeneic 
recipients along with freshly isolated WT BM cells (first BM 
Figure 7. Enhanced leukemic potential of 
BCR-ABL–induced LICs and Imatinib resis-
tance depends on cooperation between  
-catenin activation and Irf8 deficiency.  
(A and B) FACS analysis of GFP+ cells from BCR-
ABL–transduced Lin BMC at 7 (A) and 21 (B) d 
after expansion culture in vitro. GFP+ cells were 
sorted 48 h after retroviral infection and propagated 
in co-culture with OP9 stromal cells supplemented 
with SCF, Flt-3–ligand, and IL-7. (C) Kaplan-Meier 
survival curves of recipients from serial BMT as-
says. After injection of 5 × 103 sorted GFP+ cells 
plus 5 × 105 supporter cells, no significant differ-
ence in survival was evident in primary recipients 
(first BMT) bearing BCR-ABL–transfected control 
(n = 10) or Irf8/Ctnnb1(Ex3)/+ (n = 10) in com-
parison with non–BCR-ABL–transduced Irf8/ 
Ctnnb1(Ex3)/+ cells. -Catenin was activated by 
administration of poly(I:C) (injections shown as 
arrowheads). Transplantation of 5 × 103 sorted 
GFP+ cells from primary recipients and 5 × 105 
supporter cells showed a significant increase in 
disease load in Irf8/Ctnnb1(Ex3)/+ secondary 
and tertiary recipient mice (n = 10 in each BMT), 
as compared with WT controls. Log-rank (Mantel-
Cox) test. n.s., not significant; **, P < 0.001;  
***, P < 0.0001. (D) Development of aggressive CML 
BP of disease during serial transplantation in recipi-
ents bearing Irf8/Ctnnb1(Ex3)/+ GFP+ cells. Blast 
cells in BM and organ infiltrations from first and 
second BMT mice are shown by May-Grunwald-
Giemsa staining of BM smears and H&E stain of 
organs. Bars: (BM) 10 µm; (spleen, liver, and lung) 
50 µm. (E and F) -Catenin activation, Irf8 defi-
ciency, and Imatinib resistance in vitro and in vivo. 
(E) Effect of Imatinib treatment (5 µM) on LIC 
colony-forming ability in CFU assays. GFP+ cells 
from second BMT mice that were co-cultured on 
OP9 cells for 5 d in the absence or presence of  
5 µM Imatinib. Values are standardized to CFU 
number from untreated cultures in each pheno-
type and are presented as fold change, relative to 
untreated cultures in control cells (set to 1; fold 
change of CFU number in response to Imatinib 
treatment in vitro). Error bars indicate SD of trip-
licates from one experiment. Two independent 
experiments with similar outcome were done. Student´s t test. ***, P < 0.0001. (F) Imatinib administration prolongs the survival of CML-affected mice 
bearing control but not Irf8/Ctnnb1(Ex3)/+ LICs. At 7 d after second BMT (Fig. 7 C), recipients received Imatinib (n = 10 for each phenotype) or vehicle 
(control) for 70 d, and the percentage of survival was determined. Log-rank (Mantel-Cox) test. n.s., not significant; ***, P < 0.0001.
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et al., 2012). We therefore tested whether combined -catenin 
activation and loss of Irf8 synergistically interferes with Ima-
tinib response to diminish BCR-ABL–induced CML. BCR-
ABL–transformed LICs from different phenotypes were 
co-cultured with OP9 stromal cells in the presence of 5 µM 
Imatinib. WT-LICs were highly sensitive to Imatinib, as pre-
viously reported (Hurtz et al., 2011), and Imatinib treatment 
efficiently suppressed colony-forming potential in WT-BCR-
ABL cells (Fig. 7 E). This response was reduced in cells either 
being Irf8-deficient or expressing stabilized -catenin, but full 
resistance was not achieved. In contrast, Irf8/Ctnnb1(Ex3)/+ 
BCR-ABL–expressing cells showed complete Imatinib resis-
tance, indicating that both mutations synergistically mediate 
drug resistance of BCR-ABL+ leukemia (Fig. 7 E). We validated 
these results in vivo by administration of Imatinib to second 
BMT mice bearing WT or Irf8/Ctnnb1(Ex3)/+ CML-LICs. 
Indeed, Imatinib treatment failed to inhibit disease develop-
ment in recipients receiving Irf8/Ctnnb1(Ex3)/+-LICs and 
the animals developed BP and died, whereas WT-LIC recip-
ients were rescued by Imatinib treatment (Fig. 7 F). Thus, 
synergistic up-regulation of Irf8 and down-regulation of 
-catenin could be essential for sensitization of CML-LICs 
to Imatinib treatment.
Gene expression profiling of Irf8/Ctnnb1(Ex3)/+ cells 
showed up-regulation of several ABC transporter genes (Fig. 6 H), 
which had been suggested to be involved in active TKI efflux 
and TKI resistance (Zhou et al., 2001; Jordanides et al., 2006; 
Deenik et al., 2010). We therefore examined the dye-excluding 
than without it, indicating that addition of these genetic 
lesions accelerated BCR-ABL–induced leukemia progres-
sion. Absolute numbers of GFP+ Irf8/Ctnnb1(Ex3)/+-LICs 
in recipient peripheral blood were significantly higher than 
the absolute numbers of WT-LICs (96.85 ± 19.7 vs. 5.12 ± 
0.6, ×104/µl). Next, we performed serial transplantation of 
BCR-ABL+ WT- and Irf8/Ctnnb1(Ex3)/+-LICs from first 
BMT mice into a new set of recipients along with supporter 
BM cells. WT-LICs were still sufficient to induce CML in sec-
ond BMT recipients but disease development and lethality 
declined in third BMT recipients (Fig. 7 C, middle and right). 
Conversely, Irf8/Ctnnb1(Ex3)/+-LICs gave rise to an accel-
erated course of disease through serial transplantations with 
rapid generation of undifferentiated blasts in BM, spleen, and 
peripheral organs (Fig. 7 D). Notably, we observed develop-
ment of ALL or CML in second and third BMT recipients 
that had received either WT-LICs or Irf8/Ctnnb1(Ex3)/+-
LICs (unpublished data), as reported (Li et al., 1999), suggesting 
that both LICs can generate malignancies in several lineages. 
Thus, results from serial transplantation assays demonstrated 
that cooperation between activated -catenin signaling and 
Irf8 deficiency maintains a long-term leukemia-initiating 
potential with increased self-renewal activity, whereas WT-LICs 
lose their leukemia-initiating potential, probably due to a re-
duction in LIC self-renewal activity.
Previous work by others suggested that either expression 
of Irf8 or deletion of -catenin correlated with increased 
Imatinib sensitivity of CML cells (Burchert et al., 2004; Heidel 
Figure 8. Enrichment of SP cells in Irf8/ 
Ctnnb1(Ex3)/+ BM and conclusive model. (A–D) 
Hoechst 33342 profile and the immunophenotyping 
of SP cells shows. Data are mean values ± SD for 
three to four mice of each genotype. (A) Representa-
tive FACS analysis of control, Irf8/, and double-
mutated Irf8/Ctnnb1(Ex3)/+ BM cells, which were 
stained with Hoechst 33342 dye to determine the 
Hoechst effluxing SP is shown. The SP region is indi-
cated by a trapezoid on each panel. (B) Bar graph 
listing the frequency of SP cells among all single, 
viable, and nucleated cells shown in A. (C) Representa-
tive FACS profiles for LSKs represented as the percent-
age of LSK BM progenitors within gated SP cells.  
(D) Bar graph listing the frequency of LSKs within SP 
population shown in C. Statistics: (B and D) Student´s 
t test. *, P < 0.05; ***, P < 0.0001. (E) Conclusive model 
summarizing the regulatory circuitry between Irf8, 
Wnt signaling, and BCR-ABL. Scheme outlining the 
crosstalk between Wnt and IFN signaling in normal 
hematopoiesis and interference by BCR-ABL signaling. 
In normal hematopoiesis, activation of -catenin 
results in up-regulation of Irf8 (green line), which in 
turn limits oncogenic -catenin functions (red line). 
In leukemia BCR-ABL interferes with this cross talk by 
inhibiting Irf8 and by activating -catenin. Imatinib 
inhibits BCR-ABL and restores CML progression. Ad-
ditional alterations at later stages of disease confer 
BCR-ABL–independent -catenin activation and Irf8 
inhibition and thus cause Imatinib resistance.
2250 -catenin and Irf8 in leukemia progression | Scheller et al.
(Fodde et al., 2001). Collectively, it appears that the amount 
of activated -catenin in the nucleus determines the severity 
of the disease. Although because BP occurs relatively late after 
-catenin stabilization, we cannot exclude that additional 
molecular changes are required for disease progression.
Self-renewing HSCs are maintained after conditional re-
moval of -catenin, -catenin, or both, whereas aberrantly 
activated Wnt/-catenin signaling reactivates a self-renewal 
program of LICs in various hematopoietic disorders. We 
demonstrated that constitutive activation of -catenin in WT 
HSCs results in down-regulation of self-renewal–associated 
genes and up-regulation of apoptotic genes (Fig. 1 A), in ac-
cordance with previous observations (Kim et al., 2000; Perry 
et al., 2011). Indeed, competitively transplanted cells with un-
restricted -catenin activation disappeared in recipients, indi-
cating selective disadvantage of such hematopoietic progenitors 
that may be superseded only when cells become resistant to 
apoptosis (Reya et al., 2003; Perry et al., 2011). Irf8-mediated 
apoptosis and tumor suppression has been reported to occur 
in part by Bcl2 down-regulation (Tamura et al., 2003; Burchert 
et al., 2004). Moreover, stabilized -catenin was tolerated in 
myeloid cells that ectopically express Bcl2 (Reya et al., 2003). 
We therefore examined whether Bcl2 deregulation would suf-
fice for acute leukemogenic conversion after Wnt/-catenin 
signaling activation (constructing MxCre+Ctnnb1(Ex3)fl/+ and 
H2K-BCL-2 intercrosses. Although these results confirmed 
attenuated leukocytosis and expansion of the LSK compart-
ment in Bcl2 transgenic animals after stabilization of -catenin 
(unpublished data), protection from apoptosis was not suffi-
cient for myeloid leukemia development. Similarly, Irf8 hap-
loinsufficiency did not cooperate with antiapoptotic signals 
delivered by Bcl2 to promote leukemia (Koenigsmann and 
Carstanjen, 2009).
In accordance with a previous study (Baba et al., 2005), 
-catenin activation skews the lineage-priming gene pattern 
in WT HSCs and GMPs by suppression of myeloid and up-
regulation of erythroid genes (Fig. 1 A). Although myelo- 
erythroid transcriptional deregulation is often associated with 
leukemogenesis, it may thus be considered as a consequence, 
rather than the cause of malignancy (Jamieson et al., 2004; 
Rosenbauer and Tenen, 2007). Deregulation of myelo-erythroid 
lineage priming may be caused in part by enhanced Irf8 ex-
pression that acts as a myeloid gene suppressor and therewith 
restricts the myeloid lineage commitment phase that is par-
ticularly vulnerable to leukemic conversion (Kirstetter et al., 
2008; Zhang et al., 2009). Importantly, genetic ablation of Irf8 
restores the myeloid lineage capacity of GMPs, defeats apopto-
sis, and permits activated -catenin to drive leukemogenesis.
The conditional induction of BP after -catenin activa-
tion in Irf8-deficient mice permitted the direct comparison 
of gene profiles between the chronic and the acute leukemic 
phase. This revealed that progression of the disease is tightly con-
nected to the magnitude of deregulation of a gene set (PSS) 
that is already present in the CP. Consistent with this notion 
is the fact that only a modest number of genes was previ-
ously found to be differentially expressed during progression 
side population (SP) of CML-LICs to explore enhanced ef-
flux as a possible mechanism of Imatinib resistance. An in-
creased SP was detected in Irf8/Ctnnb1(Ex3)/+, as compared 
with single Irf8/ and WT Lin-depleted BM cells (Fig. 8, 
A and B). Further characterization revealed that WT con-
tained a homogenous LSK-enriched SP, whereas the Irf8/ 
Ctnnb1(Ex3)/+ SP was heterogeneous and contained more dif-
ferentiated and fewer LSK cells (Fig. 8, C and D). These results 
suggest enhanced efflux as a mechanism of resistance to Ima-
tinib therapy.
DISCUSSION
The clinical observation of Irf8 deficiency and enhanced 
Wnt/-catenin pathway activity predicts poor prognosis in 
the progression of myeloid leukemia (Schmidt et al., 2001; 
Jamieson et al., 2004). However, genetic evidence of func-
tional interaction between both genetic lesions was missing. 
Using conditional gene targeting in mice, we show a direct 
cross-regulatory relationship between Irf8 and canonical Wnt 
signaling in leukemia, as depicted in Fig. 8 E. Previously, we 
and others showed that activation of -catenin in WT HSCs 
failed to induce leukemia (Kirstetter et al., 2006; Scheller 
et al., 2006). Here, we demonstrate that this failure is caused 
by a feedback loop between the Wnt/-catenin signaling 
and the Irf8 gene. Loss of Irf8 led to preleukemic myelo-
proliferation, which required -catenin. Increasing the dos-
age of activated -catenin in Irf8-deficient cells advanced the 
chronic CML into an acute disease phase, providing genetic 
evidence that Irf8 is a roadblock for -catenin–induced leu-
kemogenesis. Accordingly, -catenin activation in combination 
with Irf8 deficiency represent molecular events that increase 
the leukemic potential of BCR-ABL–transformed LICs, ag-
gressiveness of CML progression, and rendered LICs resistant 
to Imatinib (Fig. 8 E).
The murine model described here recapitulates both 
phases of classical human CML: (1) an initial semi-stable CP 
that entails compromised Irf8 expression and low-level nuclear 
-catenin expression; and (2) a subsequent acute and fatal BP 
that entails strongly increased accumulation of nuclear -catenin 
combined with loss of Irf8. How Irf8 could reduce -catenin 
nuclear accumulation is issue of further studies, although a 
possible explanation relates to altered proteasomal degrada-
tion. In Irf8/ cells, transcripts encoding ubiquitin-mediated 
proteolysis pathway components including Cul4b, Fbxw4, 
Ubfd1, and Rhobtb1, are down-regulated. It has been shown 
that these gene products may be involved in -catenin turn-
over (Aberle et al., 1997). Thus, different quantities of 
activated -catenin drive the chronic and acute leukemo-
genic phases. Similarly, LICs in MLL-induced leukemia were 
demonstrated to express high levels of activated -catenin, 
as compared with pre-LICs (Yeung et al., 2010). It has also 
been proposed that Wnt/-catenin signaling regulates nor-
mal adult hematopoiesis in a dosage-dependent manner (Luis 
et al., 2011) and that the degree of activated -catenin in a “just-
right” signaling model, as proposed for allophycocyanin (APC), 
could be relevant for tumor formation in different tissues 
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were either Irf8-deficient or expressing stabilized -catenin, 
and without effect in cells that combined both lesions. The 
mechanisms of Imatinib resistance comprise acquisition of 
point mutations in the BCR-ABL kinase domain (Shah et al., 
2004), BCR-ABL amplification (Gorre et al., 2001), variabil-
ity in the amount and function of the drug efflux protein, 
or resistance that occurs by additional mutations at the level 
of LICs that are not fully understood. Our results suggest 
that Irf8 deletion plus -catenin activation is responsible for 
treatment resistance and survival of BCR-ABL CML-LICs. 
Moreover, we have shown here that Wnt/-catenin pathways 
and Irf8 deficiency cooperate to provide a higher degree of 
Imatinib resistance than the Wnt/-catenin pathway alone. 
Before the introduction of Imatinib, IFN- was widely used 
in CML treatment. Notably, IFN- induced Irf8 in BCR-
ABL–transformed cells and protected against CML develop-
ment (Nardi et al., 2009). The exact mechanism of action 
of IFN- in the treatment of CML patients has not been 
fully revealed; however, enhanced Irf8 expression emerges as a 
likely candidate.
In summary, the analogy of the genetic mouse model and 
human myeloid leukemia let us to conclude that increasing 
the dosage of canonical Wnt signaling under Irf8 decline lever-
ages progression of the disease from chronic into a BP and 
results in accumulation of TKI-resistant LICs. We conclude 
that future therapeutic concepts may consider measures to 
elevate Irf8 expression and/or to abrogate -catenin activa-
tion in myeloid leukemogenesis, especially in the context of 
disease relapse.
MATERIALS AND METHODS
Mice and genotyping. MxCre transgenic (Kühn et al., 1995), Irf8/ 
(Holtschke et al., 1996), and mouse strains possessing the floxed alleles of Exon3 
of -catenin, Ctnnb1(Ex3)fl/fl (Harada et al., 1999), as well as the -catenin floxed 
allele Ctnnb1fl/fl (Huelsken et al., 2001) have been previously described. Mice 
were genotyped using PCR, and primer sequences have been previously de-
scribed (Holtschke et al., 1996; Domen et al., 1998; Huelsken et al., 2001; 
Scheller et al., 2006). MxCre+Ctnnb1(Ex3)fl/fl, Irf8/MxCre+Ctnnb1(Ex3)fl/fl, 
MxCre+Ctnnb1fl/fl, and Irf8/ MxCre+Ctnnb1fl/fl mice were backcrossed for at 
least eight generations to the C57BL/6 background for all experiments, and 
MxCre littermates were used as controls. Congenic B6.SJL-PtprcaPep3b/BoyJ 
(here called B6.SJL) mice were originally obtained from Charles River and 
used as recipients for BM cell transplantation. Imatinib mesylate (Enzo Life 
Sciences) was administrated to mice by oral gavage twice a day (2 × 100 mg/kg 
of body weight per day in water). All mice were maintained under specific 
pathogen-free animal facilities at the MDC/Charité. All animal experiments 
were approved by the Commission for Animal Experiments at the MDC and 
the Berlin Office of Health (LAGeSo). Survival curves were calculated by the 
method of Kaplan-Meier, and statistical analysis was performed using Prism 
(version 5.0; GraphPad Software).
Retroviruses and transduction of cells. MSCV-Irf8-IRES-GFP and 
chimeric MSCV-Irf8-ERT2-IRES-GFP constructs were donations from 
D. Carstanjen (FMP, Berlin, Germany). MSCV--catGSK-IRES-GFP con-
struct was a gift from T. Reya (Duke University, Durham NC) and p210BCR-
ABL-IRES-GFP control was a gift from A. Burchert (UKGM, Marburg, 
Germany). MSCV-IRES-GFP (MIG) construct was used as a control. The 
retrovirus packaging cell line (Phoenix-gp cells) was obtained from American 
Type Culture Collection. Virus production and cell infection was performed 
as described previously (Scheller et al., 2006).
of human CML disease; 34 genes were associated with 
CML progression and malignancy of blasts, and 6 genes were 
proposed as diagnostic markers (Zheng et al., 2006; Oehler 
et al., 2009).
Gene expression profiling of the GMP-like population 
in BP revealed a signature shared with MLL-AF9–transformed 
AML (Krivtsov et al., 2006) and with up-regulated gene set 
from human CML patients (Diaz-Blanco et al., 2007). Nota-
bly, Hoxa9, Meis1, and Mef2c genes that are characteristic for 
MLL rearrangements and an HSC-associated self-renewal 
signature were down-regulated in GMPs from BP, indicating 
that transformation in the GMP compartment may also occur 
without deregulation of these genes, although their impor-
tance has been shown in human MLL-induced AML (Krivtsov 
et al., 2006; Wang et al., 2010).
Enrichment of human CML-related genes indicated con-
vergence of BCR-ABL with Wnt/-catenin and Irf8 signal-
ing in disease progression. Within the group of deregulated 
genes, we found association with enhanced glycolysis in ac-
cordance with gene expression analysis in human CML BP 
(A et al., 2010). Interestingly, leukemic GMPs also show up-
regulation of Hif1, as a potential cause of metabolic repro-
gramming (Zhao et al., 2010). This phenomenon is related to 
the Warburg effect and is considered as one of the most fun-
damental metabolic changes that occur during malignant 
transformation. Activated VEGF, insulin, and MAPK pathways 
(which are partially overlapping) were also evident. Many 
reports have documented a role of insulin as well as Igf1 in a 
variety of cancers to provide antiapoptotic and proliferation 
stimuli (Pollak, 2008).
Growing evidence suggests that resistance to BCR-ABL 
inhibition involves increased drug export and/or altered intra-
cellular signaling (Raaijmakers, 2007; Corrêa et al., 2012). 
Both mechanisms can be mediated by the efflux transporters 
Abcc4, Abcc5, and Abcc11, which are involved in discharging 
endogenous signaling molecules and nucleoside analogues. 
It has previously been shown that Wnt/-catenin directly 
regulates ABCB1 transporter gene transcription in CML and 
other malignancies (Corrêa et al., 2012; Stein et al., 2012), and 
that enforced expression of Irf8 antagonized BCR-ABL 
and overcame drug resistance (Burchert et al., 2004). It was 
therefore interesting to see that the leukemic GMP fraction 
displayed enhanced expression of the ABC superfamily of 
efflux pumps. ABC family transporters have been reported 
to be involved in active TKI efflux and TKI resistance (Zhou 
et al., 2001; Jordanides et al., 2006; Deenik et al., 2010). We 
were also able to show enrichment of SP population in dou-
ble mutated GMPs. The SP phenotype might explain the re-
sistance of a subpopulation of leukemic cells to chemotherapy 
and represent one of the putative cancer stem cell populations 
(Golebiewska et al., 2011). Additional genes involved in drug 
resistance include Ptgs1/Cox1 and Bcl6, both of which were 
also up-regulated in the leukemic GMP from blast-crisis 
(Zhang et al., 2009; Duy et al., 2011; Hurtz et al., 2011).
Our data show that inhibition of the BCR-ABL kinase by 
Imatinib was effective in WT, less so in single mutant cells that 
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blood parameters. Red blood cells were lysed on ice using hypotonic eryth-
rocyte lysis buffer (Pharmlyse buffer; BD). Cell staining and sorting was per-
formed using Pacific blue, FITC, PE, APC, PE-Cy5, PE-Cy7, APC-Cy7, 
or biotin-labeled monoclonal antibodies directed against CD45.1 (A20), 
CD45.2 (104), B220 (6B2), CD19 (1D3), IL-7R chain (SB/199), CD3 
(KT31.1), CD4 (GK1.5), CD8 (53–6.7), CD25 (3C7), CD44 (IM7), DX5, 
Gr1 (RB6.8C5), Mac1/CD11b (M1/70), Ter119, CD71 (C2), CD41 
(MWReg30), c-Kit (2B8), Sca-1 (E13-161-7), CD34 (RAM34), FcRII/III 
(2.4G2), CD135/Flt-3 (A2F10.1), and CD150/Slam (TC15-12F12.2; BD 
and eBioscience).
Cells were analyzed with FACSCalibur, FACSCanto II, or LSR II or 
sorted using FACSAria (BD) flow cytometers. Nonspecific antibody binding 
was reduced by preincubation with unconjugated antibody to FcRII/III 
(2.4G2). Dead cells were excluded by propidium iodide or 7-AAD staining. 
Cell staining was performed using monoclonal antibodies described in supple-
mentary information. Lineage-negative BM fraction was prepared by labeling 
cell suspensions with a mixture of antibodies to CD3e, CD4, CD8a, CD19, 
B220, Gr1, Il-7R, and Τ119. Lin+ cells were partially removed by using 
magnetic bead depletion (sheep anti–rat IgG-conjugated Dynabeads; Invitro-
gen). The LSK fraction of the BM, enriched for HSCs and MPPs, was stained 
and defined as LSK), whereas the HPCs (defined as LinSca-1–c-Kit+) contain 
CMPs (defined as LinSca-1c-Kit+CD34+FcR II/IIIlo), GMPs (LinSca-1 
c-Kit+CD34+FcR II/IIIhi), and MEPs (LinSca-1c-Kit+CD34FcR II/III; 
Iwasaki and Akashi, 2007). For Annexin V staining, freshly isolated BM cells 
were stained with appropriate antibody, washed in binding buffer, and incu-
bated in the dark with Annexin V–FITC or –APC (BD) for 20 min at 4°C. For 
SP cell analyses were done exactly as previously described (Ergen et al., 2013). 
Data were analyzed using CellQuest or FlowJo (Tree Star).
Colony-forming assay. Colony assay in methylcellulose were performed 
using MethoCult GF M3434 (STEMCELL Technologies) supplemented 
with 50 ng/ml rmSCF, 10 ng/ml rmIL-3, 10 ng/ml rhIL-6, and 3 U/ml 
rhEpo. Fixed numbers (2 × 104 BM or 105 spleen cells/ml) were seeded in 
triplicate into 35 mm2 Petri dishes and incubated at 37°C in a humidified at-
mosphere of 5% CO2 in air. Individual colonies (defined by >100 cells) were 
scored at 5–7 d after plating. For serial replating assays, cells were replated at 
1-wk intervals for five rounds. Two independent experiments in triplicates 
each were performed and the number of colonies was compared using a 
paired Student’s t test.
For WT and/or Irf8/ BM cells infected with MSCV-Irf8-IRES-eGFP 
(provided by D. Carstanjen), MSCV--catGSK-IRES-eGFP (provided by 
T. Reya) and control MIG construct, GFP+ cells were first sorted and seeded 
in in methylcellulose cultures (M3434, STEMCELL Technologies) as described 
above. Two independent experiments in triplicates were performed.
Quantitative RT-PCR. Total RNA from cells was extracted using RNeasy 
mini or micro kit from (QIAGEN). cDNA was generated using a poly(dT) 
oligonucleotides and SuperScript II Reverse Transcription (SuperScript II 
kit; Invitrogen) or using the Revert Aid First Strand cDNA Synthesis kit 
(Fermentas) and amplified on a 7300 Real Time PCR System (Applied Bio-
systems) using TaqMan probes for Irf8. Gene expression was normalized to 
-actin (ABI: 4352341E). Alternatively, qRT-PCR reactions were performed 
using Platinum-SYBR green (Invitrogen) mix on the LightCycler 2.0 
(Roche) system according to the manufacturer’s instructions. At least tripli-
cate reactions were performed for each gene. Melting curve analysis was per-
formed after each run to control for the nonspecific PCR products and 
primer dimers. Ct values were related to copy numbers using standard curves. 
For each gene examined, a specific PCR fragment was synthesized that was 
extended at least 20–30 bp upstream and downstream of the amplicon gener-
ated by the primers used for the qRT-PCR. Normalization was performed 
using -actin as an internal control. Primers for quantitative RT-PCR are 
listed in Tables S1 and S2.
Protein analysis. Lineage-depleted BM cells were lysed in buffer A (10 mM 
Hepes, pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, and 0.1% 
NP-40) and subfractionated into cytosolic and nuclear membrane fractions by 
Mouse transplantation experiments and generation of CML model. 
Freshly isolated BM cells were injected (2 × 106 cells/mouse) through the tail 
vein into lethally irradiated (9.5–10 Gy total body irradiation, Cs-137 source) 
B6.SJL recipient mice. Primary recipient mice were maintained on Sulfa-
doxin/Trimethoprim drinking water (40/8 mg/kg as a 0.1% Borgal, 1 wk) 
and allowed to engraft for 6 wk before being used for analysis. Repopulation 
was determined every 4 wk after transplantation by collection of peripheral 
blood, erythrocyte lysis, and staining of CD45.1 (Ly5.1; recipient) versus 
CD45.2 (Ly5.2; donor) engraftment. -Catenin deletion or -catenin acti-
vation (excision of Exon3 in the -catenin gene) was induced by three i.p. 
injections of 400 µg poly(I:C) (GE Healthcare) in PBS on days 0, 3, and 5. 
Analysis of mice or harvesting of BM cells were performed 10–14 d after the 
last poly(I:C) injection. In all experiments, recipients transplanted with MxCre 
Ctnnb1(Ex3)fl/+, Irf8/MxCre–Ctnnb1(Ex3)fl/+, MxCreCtnnb1fl/fl, or Irf8/ 
MxCreCtnnb1fl/fl BM cells were used as controls for nonspecific poly(I:C) 
effects. In all experiments with activated -catenin, we used heterozygous 
inducible MxCre+Ctnnb1(Ex3)fl/+ mice because of the dominant effect from a 
single activated Ctnnb1 allele. To validate excision efficiency, genomic DNA 
from blood or harvested cells was subjected to PCR, as previously described 
(Huelsken et al., 2001; Scheller et al., 2006).
For investigation of Irf8 overexpression, magnetically enriched hematopoi-
etic progenitor cells (HPCs) and HSCs from C57/BL6 mice were infected 
with a retroviral vector expressing 4-OHT–inducible Irf8 (Irf8-ERT2-MIEG3) 
or control construct (ERT2-MIEG3) and injected (2 × 106/mouse, 12.3–15% 
GFP-positive cells) in lethally (9.5 Gy) irradiated C57/BL6 mice. Irf8 over-
expression was induced 5 and 7 wk after transplantation by i.p. injection of 
4-OHT every day for 5 d, using 1 mg per mouse dissolved in 100 µl of corn 
oil. Mice were analyzed biweekly after transplantation for evaluation of GFP+ 
cell expansion in peripheral blood.
To generate the BCR-ABL–inducible CML model, Lin BM cells from 
Irf8/MxCre+Ctnnb1(Ex3)fl/+, Irf8/MxCreCtnnb1(Ex3)fl/+, Irf8+/+MxCre+ 
Ctnnb1(Ex3)fl/+, and control littermate Irf8+/+MxCreCtnnb1(Ex3)fl/+ mice were 
infected with p210BCR-ABL-IRES-GFP virus construct containing super-
natant medium. GFP+ 7-AAD–negative progenitors were sorted 48 h after 
infection and co-cultured with OP9 stromal cells plus stem cell factor (SCF), 
Flt-3–ligand, and IL-7 (R&D Systems) for an additional 21 d. After expan-
sion, 5,000 sorted GFP+c-Kit+CD11b+ cells were transplanted intravenously 
into lethally irradiated (9.5 Gy) congenic recipient mice, along with 5 × 105 
normal BM cells from B6.SJL (Ly5.1+) mice. -Catenin activation was in-
duced by three i.p. injections of 400 µg poly(I:C) every 2nd d as described 
above/earlier. For serial transplantations, GFP+ CML-LICs (5,000 or 10,000) 
were collected and pooled from two to three BMT mice and transplanted 
into a second set of lethally irradiated congenic recipient mice, along with 
5 × 105 normal BM cells from B6.SJL (Ly5.1+) mice. Mice were monitored 
daily for cachexia, lethargy, and ruff coats and moribund mice were killed. 
Leukemia was determined in peripheral blood, BM, spleen, and peripheral 
organs by FACS and histological analysis.
In vitro co-culture and Imatinib treatment. BCR-ABL–transduced 
GFP+c-Kit+ cells were sorted from the BM of second BMT mice after poly(I:C) 
treatment and development of clinically evident blast crisis. 104 freshly iso-
lated cells were co-cultured with OP9 stromal cells supplemented with SCF, 
Flt-3-ligand, and IL-7 (R&D Systems) in the presence or absence of 5 µM 
Imatinib for 5 d. Colony formation was assessed by plating 103 cells into 
semisolid medium (M3434). Individual colonies were scored at 5 d after plat-
ing, and total number of cells were harvested, counted, and frequency of GFP+ 
cells analyzed by FACS.
Cells preparation, FACS analysis, sorting, and SP cell staining. BM 
cell suspensions were prepared by flushing femurs and tibias with PBS. Cell 
suspensions from organs (spleen, liver, lymph nodes, and thymus) were ob-
tained using 70-µm cell strainers (Falcon; BD). Peripheral blood samples 
were obtained from the tail vein and collected in EDTA-coated tubes. The 
blood cell counts were performed with automated veterinary hematological 
counter Scil Vet abc Plus+ (SCIL GmbH), with software optimized for mouse 
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data analysis, we used the corresponding affy/limma package functions of the 
Bioconductor system. Raw microarray data from Affymetrix CEL files were 
normalized using RMA. Quality Control identified 0 outliers. For identifi-
cation of differentially expressed genes, we fitted a linear model using limma. 
The fold change cutoff was set to |1.5|, and the multiple testing corrected 
(Benjamini-Hochberg) p-value cutoff was selected as 0.05. For functional 
analysis, we used GSEA v2.0 algorithm (http://www.broadinstitute.org/gsea) 
using the computed t-statistic from limma as preranking. Microarray data 
(PSS) were uploaded to the Gene Expression Omnibus under accession no. 
GSE49054, showing the list of 638 genes (EntrezID, 394 UP, 244 DN) that 
were up- and down-regulated in Irf8/Ctnnb1(Ex3)/+ GMPs from BP as 
compared with control GMPs.
Gene expression profiles of CML patient samples have been described 
previously (Radich et al., 2006). The data were downloaded from GEO 
(GSE4170) and analyzed for expression of IRF8 and Wnt target genes (Roel 
Nusse, the Wnt Homepage) in BM and PB samples from 42 chronic, 17 accel-
erated, and 32 BP CML patients using R/Bioconductor. For preprocessing, 
quantile normalization was applied. We assessed the statistically significant 
difference between IRF8 expression in the chronic group (CP) and the pro-
gression group (BC+AP) with a moderated t test (limma, P < 0.05). The same 
procedure was applied to a set of genes involved in Wnt target genes. Here, 
we compared samples from the progression group (BP) with the samples from 
the chronic group (CP) based on their IRF8 expression status.
We computed statistical significance of experimental results using two-
tailed paired or unpaired Student’s t tests. A p-value of <0.05 was considered 
statistically significant and marked by an asterisk. Two asterisks represent p-values 
of <0.001, whereas three asterisks represent p-values of <0.0001.
Online supplemental material. Table S1 shows primers for RT-PCR. 
Table S2 shows primers for TaqMan. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20130706/DC1.
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Table S1. PrimersforRT-PCR
Gene Primer
Irf8 (f) 5-GCTGATCAAGGAACCTTGTG-3
(r) 5-CAGGCCTGCACTGGGCTG-3
Cebpa (f) 5-TGCTGGAGTTGAGTGAC-3
(r) 5-CTTGACCAAGGAGCTCTCAG-3
Sfpi/Pu.1 (f) 5-GTCACCAGGTTTCCTACATGC-3
(r) 5-CTCTGCCTCTCACCCTCCT-3
Bcl2 (f) 5-GAGGCTGGGATGCCTTTGT-3
(r) 5-AGGCTGAGCAGGGTCTTCAG-3
Actb (f) 5-GACGGCCAGGTCACTATTG-3
(r) 5-AGGAAGGCTGGAAAAGAGCC-3
f,forward;r,reverse.
Table S2. PrimersforTaqMan
Gene Primer
Irf8 FW: 5-CAGGCCTGCCACTGGTG-3
RV: 5-CCACTGGGAGAAAGCTGAATG-3
Probe: 6FAM-CCGGATATGCCGCCTATGACACACA-TAMRA
Sfpi/Pu.1 FW: 5-AGAAGCTGATGGCTTGGAGC-3
RV: 5-GCGAATCTTTTTCTTGCTGCC-3
Probe: FAM-TGGGCCAGGTCTTCTGCACGG-TAMRA
Cebpa Mm00514283 (ABI)
Actb 4352341E (ABI)
FW,forward;RV,reverse.
